Therapeutic Potential of Seaweed-Derived Bioactive Compounds for Cardiovascular Disease Treatment
Source abstract
Abstract
Cardiovascular diseases are closely related to hypertension, type 2 diabetes mellitus, obesity, and hyperlipidemia. Many studies have reported that an unhealthy diet and sedentary lifestyle are critical factors that enhance these diseases. Recently, many bioactive compounds isolated from marine seaweeds have been studied for their benefits in improving human health. In particular, several unique bioactive metabolites such as polyphenols, polysaccharides, peptides, carotene, and sterol are the most effective components responsible for these activities. This review summarizes the current in vitro, in vivo, and clinical studies related to the protective effects of bioactive compounds isolated from seaweeds against cardiovascular disorders, including anti-diabetic, anti-hypertensive, anti-hyperlipidemia, and anti-obesity effects. Therefore, this present review summarizes these concepts and provides a basis for further in-depth research.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Seaweed-derived Bioactive Compounds · Protein Hydrolysis and Bioactive Peptides · Biochemical effects in animals
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Korea Food Research Institute, 245 Nongsaengmyeong-ro, Iseo-myeon, Wanju-gun 55365, Korea
Department of Marine Life Science, Jeju National University, Jeju 63243, Korea
Department of Food Biotechnology, Korea University of Science and Technology, 217 Gajeong-ro, Yuseong-gu, Daejeon 34113, Korea
Marine Science Institute, Jeju National University, Jeju 63333, Korea
Funding
Ministry of Science and ICT
References (100+)
Show source-provided references
1. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 201510.1016/j.jacc.2017.04.052 ↗
2. Conjoint Associations of Gestational Diabetes and Hypertension with Diabetes, Hypertension, and Cardiovascular Disease in Parents: A Retrospective Cohort Study10.1093/aje/kwx263 ↗
3. Obesity and hypertension10.1016/j.phrs.2017.05.013 ↗
4. The relationship between obesity and hypertension: An updated comprehensive overview on vicious twins10.1038/hr.2017.75 ↗
5. Regulation of vascular tone homeostasis by NO and H2S: Implications in hypertension10.1016/j.bcp.2018.01.017 ↗
6. Cardiovascular disease risk factors: Hypertension, diabetes mellitus and obesity among Tabuk citizens in Saudi Arabia10.2174/1874192401812010041 ↗
7. Chlinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial10.1161/01.HYP.0000231662.77359.de ↗
8. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk10.1111/j.1742-1241.2008.01713.x ↗
9. Inositol 1,4,5-trisphosphate receptors in endothelial cells play an essential role in vasodilation and blood pressure regulation10.1161/JAHA.118.011704 ↗
10. Seaweed: Promising plant of the millennium
11. Prebiotics from marine macroalgae for human and animal health applications10.3390/md8072038 ↗
12. Bioactive compounds in seaweeds: An overview of their biological properties and safety10.1016/j.fct.2019.111013 ↗
13. Seaweed nutraceuticals and their therapeutic role in disease prevention10.1016/j.fshw.2019.08.001 ↗
14. Therapeutic potential of algal natural products against metabolic syndrome: A review of recent developments10.1016/j.tifs.2020.01.020 ↗
15. Bio-vunctionalities of proteins derived from marine algae—A review10.1016/j.foodres.2012.03.013 ↗
16. In the search of new functional food ingredients from algae10.1016/j.tifs.2007.07.012 ↗
17. Structure/function analysis of a type III polyketide synthase in the brown alga Ectocarpus Siliculosus reveals a biochemical pathway in phlorotannin monomer biosynthesis10.1105/tpc.113.111336 ↗
18. Phlorotannins from Ecklonia cava (Phaeophyceae): Biological activities and potential health benefits10.1002/biof.114 ↗
19. Phloroglucinol compounds of natural origin10.1039/b600518g ↗
20. Chemical modification of tannins to elaborate aromatic biobased macromolecular architectures10.1039/C5GC00282F ↗
21. Phlorotannins: A review of extraction methods, structural characteristics, bioactivities, bioavalability, and future trends10.1016/j.algal.2021.102484 ↗
22. Phlorotannins: A review on biosynthesis, chemistry and bioactivity10.1016/j.fbio.2020.100832 ↗
23. Seca, A.M.L., and Pinto, D.C.G.A. (2018). Overview on the antihypertensive and anti-obesity effects of secondary metabolites from seaweeds. Mar. Drugs, 16.10.3390/md16070237 ↗
24. Exploiting biological activities of brown seaweed Ecklonia cava for potential industrial applications: A review10.3109/09637486.2011.619965 ↗
25. History of the design of captopril and related inhibitors of angiotensin converting enzyme10.1161/01.HYP.17.4.589 ↗
26. Effect of phlorotannins isolated from Ecklonia cava on angiotensin I-convering enzyme (ACE) inhibitory activity10.4162/nrp.2011.5.2.93 ↗
27. Angiotensin-converting enzyme I inhibitory activity of phlorotannins from Ecklonia stolonifera10.1111/j.1444-2906.2006.01288.x ↗
28. Effect of angiotensin I-convering enzyme (ACE) inhibition and nitric oxide (NO) production of 6,6’-bieckol, a marine algal polyphenol and its anti-hypertensive effect in spontaneously hypertensive rats10.1016/j.procbio.2017.04.014 ↗
29. Angiotensin I-converting enzyme (ACE) inhibition and nitric oxide (NO)-mediated antihypertensive effect of oxtaphorethol A isolated from Ishige sinicola: In vitro molecular mechanism and in vivo SHR model10.1016/j.jff.2015.07.003 ↗
30. Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: Mechanisms and implications10.1152/ajpcell.00282.2016 ↗
31. Analysing calcium dependent and independent regulation of eNOS in endothelium triggered by extracelluar signalling events10.1039/c3mb70258h ↗
32. Life history of eNOS: Partners and pathways10.1016/j.cardiores.2007.03.023 ↗
33. Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension10.2174/1874467211104030176 ↗
34. cGMP-dependent relaxation of smooth muscle is coupled with the change in the phosphorylatin of myosin phophatase10.1161/CIRCRESAHA.107.153981 ↗
35. Lu, Y.-A., Je, J.-G., Hwang, J., Jeon, Y.-J., and Ryu, B. (2021). Ecklonia cava extract and its derivative dieckol promote vasodilation by modulating calcium signaling and PI3K/AKT/eNOS pathway in in vitro and in vivo model. Biomedicines, 9.10.3390/biomedicines9040438 ↗
36. Lu, Y.A., Jiang, Y., Yang, H.-W., Hwang, J., Jeon, Y.-J., and Ryu, B. (2021). Diphlorethohydroxycarmalol isolated from Ishige okamurae exerts vasodilatory effects via calcium signaling and PI3K/Akt/eNOS pathway. Int. J. Mol. Sci., 22.10.3390/ijms22041610 ↗
37. Oh, S., Son, M., Lee, H.S., Kim, H.-S., Jeon, Y.-J., and Byun, K. (2018). Protective effect of pyrogallol-phloroglucinol-6,6-bieckol from Ecklonia cava on monocyte-associated vascular dysfunction. Mar. Drugs, 16.10.20944/preprints201810.0530.v1 ↗
38. Son, M., Oh, S., Lee, H.S., Ryu, B., Jiang, Y., Jang, J.T., Jeon, Y.-J., and Byun, K. (2019). Pyrogallol-phloroglucinol-6,6’-bieckol from Ecklonia cava improved blood circulation in diet-induced obese and diet-induced hypertension mouse model. Mar. Drugs, 17.10.3390/md17050272 ↗
39. Flavonoids and cardiovascular disease10.3109/13880200490893483 ↗
40. Clinical effects of brown seaweed, Undaria pinnatifida (wakame), on blood pressure in hypertensive subjects10.3164/jcbn.30.43 ↗
41. Murray, M., Dordevic, A.L., Ryan, L., and Bonham, M.P. (2018). The impact of a single dose of a polyphenol-rich seaweed extract on postprandial glycaemic control in healthy adults: A randomised cross-over trial. Nutrients, 10.10.3390/nu10030270 ↗
42. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment10.1016/S0140-6736(06)69700-6 ↗
43. Dietary polyphenols as potential nutraceuticals in management of diabetes: A review10.1186/2251-6581-12-43 ↗
44. Anti-diabetic potential of phenolic compounds: A review10.1080/10942912.2011.595864 ↗
45. Re-exploring promising α-glucosidase inhibitors for potential development into oral anti-diabetic drugs: Finding needle in the haystack10.1016/j.ejmech.2015.08.043 ↗
46. An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications10.1016/j.fct.2020.111738 ↗
47. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus10.1080/00498254.2016.1275063 ↗
48. Inhibitory activity of minor phlorotannins from Ecklonia cava on α-glucosidase10.1016/j.foodchem.2018.03.013 ↗
49. α-Glucosidase and α-amylase inhibitory activities of phloroglucinal derivatives from edible marine brown alga, Ecklonia cava10.1002/jsfa.3623 ↗
50. A phlorotannin constituent of Ecklonia cava alleviates postprandial hyperglycemia in diabetic mice10.1080/13880209.2017.1291693 ↗
51. Dieckol isolated from Ecklonia cava inhibits α-glucosidase and α-amylase in vitro and alleviates postprandial hyperglycemia in streptozotocin-induced diabetic mice10.1016/j.fct.2010.06.032 ↗
52. Protein tyrosine phosphatase 1B and α-glucosidase inhibitory phlorotannins from edible brown algae, Ecklonia stolonifera and Eisenia bicyclis10.1271/bbb.110137 ↗
53. Ryu, B., Jiang, Y., Kim, H.-S., Hyun, J.-M., Lim, S.-B., Li, Y., and Jeon, Y.-J. (2018). Ishophloroglucin A, a novel phlorotannin for standardizing the anti-α-glucosidase activity of Ishige okamurae. Mar. Drugs, 16.10.3390/md16110436 ↗
54. Octaphlorethol A: A potent α-glucosidase inhibitor isolated from Ishige foliacea shows an anti-hyperglycemic effect in mice with streptozotocin-induced diabetes10.1039/C4FO00420E ↗
55. Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent α-glucosidase and α-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice10.1016/j.ejphar.2009.05.017 ↗
56. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci., 21.10.3390/ijms21176275 ↗
57. The dynamic plasticity of insulin production in β-cells10.1016/j.molmet.2017.04.010 ↗
58. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes10.2174/157339913804143225 ↗
59. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders10.1016/j.diabet.2007.10.004 ↗
60. 2,7”-Phloroglucinol-6,6’-bieckol pretects INS-1 cells against high glucose-induced apoptosis10.1016/j.biopha.2018.04.129 ↗
61. Dieckol isolated from brown seaweed Ecklonia cava attenuates type Ⅱ diabetes in db/db/ mouse model10.1016/j.fct.2012.12.012 ↗
62. Yang, H.-W., Son, M., Choi, J., Oh, S., Jeon, Y.-J., Byun, K., and Ryu, B. (2019). Effect of ishophloroglucin A, a component of Ishige okamurae, on glucose homeostasis in the pancreas and muscle of high fat diet-fed mice. Mar. Drugs, 17.10.3390/md17110608 ↗
63. Octaphlorethol A, a marine algae product, exhibits antidiabetic effects in type 2 diabetic mice by activating AMP-activated protein kinase and upregulating the expression of glucose transporter 410.1016/j.fct.2016.02.022 ↗
64. Fernando, K.H.N., Yang, H.-W., Jiang, Y., Jeon, Y.-J., and Ryu, B. (2018). Diphlorethohydroxycarmalol isolated from Ishige okamurae represses high glucose-induced angiogenesis in vitro and in vivo. Mar. Drugs, 16.10.3390/md16100375 ↗
65. Fernando, K.H.N., Yang, H.-W., Jiang, Y., Jeon, Y.-J., and Ryu, B. (2019). Ishige okamurae extract and its constituent ishophloroglucin A attenuated in vitro and in vivo high glucose-induced angiogenesis. Int. J. Mol. Sci., 20.10.3390/ijms20225542 ↗
66. Molecular mechanism of obesity-induced ‘metabolic’ tissue remodeling10.1111/jdi.12769 ↗
67. Adipose tissue remodeling and obesity10.1172/JCI45887 ↗
68. A cellular perspective of adipogenesis transcriptional regulation10.1002/jcp.27060 ↗
69. Xanthigen attenuates high-fat diet-induced obesity through down-regulation of PPARγ and activation of the AMPK pathway10.1007/s10068-014-0125-1 ↗
70. Phlorotannins suppress adipogensis in pre-adipocytes while enhancing osteoblastogenesis in pre-osteoblasts10.1007/s12272-015-0637-0 ↗
71. Dieckol, a phlorotannin isolated from a brown seaweed, Ecklonia cava, inhibits adipogenesis through AMP-activated protein kinase (AMPK) activation in 3T3-L1 preadipocytes10.1016/j.etap.2013.10.011 ↗
72. Dieckol, a major phlorotannin in Ecklonia cava, suppresses lipid accumuation in the adipocytes of high-fat diet-fed zebrafish and mice: Inhibition of early adipogensis via cell-cycle arrest and AMPKα activation10.1002/mnfr.201500021 ↗
73. Phlorotannins isolated from the edible brown alga Ecklonia stolonifera exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBPα and PPARγ10.1016/j.fitote.2013.12.003 ↗
74. 6,6’-Bieckol inhibits adipocyte differentiation through downregulation of adipogenesis and lipogenesis in 3T3-L1 cells10.1002/jsfa.6881 ↗
75. Effect of diphlorethohydroxycarmalol isolated from Ishige okamurae on apoptosis in 3T3-L1 preadipocytes10.1002/ptr.4797 ↗
76. Diphlorethohydroxycarmalol of Ishige okamurae and caffeine modified the expression of extracellular fibrillars during adipogenesis of mouse subcutaneous adipose derived stem cell10.12717/DR.2013.17.3.275 ↗
77. Kang, M.-C., Ding, Y., Kim, H.-S., Jeon, Y.-J., and Lee, S.-H. (2019). Inhibition of adipogenesis by diphlorethohydroxycarmalol (DPHC) through AMPK activation in adipocytes. Mar. Drugs, 17.10.3390/md17010044 ↗
78. Pancreatic lipase inhibitory activity of phlorotannins isolated from Eisenia bicyclis10.1002/ptr.4694 ↗
79. Oh, S., Son, M., Choi, J., Choi, C.H., Park, K.Y., and Son, K.H. (2019). Phlorotannins from Ecklonia cava attenuates plamitate-induced endoplasmic reticulum stress and leptin resistance in hypothalamic neurons. Mar. Drugs, 17.10.3390/md17100570 ↗
80. Inhibitory activity of Ecklonia stolonifera and its isolated phlorotannins against Cu2+-induced low-density lipoprotein oxidation10.1007/s12562-012-0511-7 ↗
81. Anti-hyperlipidemic effect of an edible brown algae, Ecklonia stolonifera, and its constituents on polyxamer 407-induced hyperlipidemic and choloesterol-fed rats10.1007/s12272-001-2152-8 ↗
82. Anti-hyperlipidemic effect of polyphenol extract (SeapolynolTM) and dieckol isolated from Ecklonia cava in in vivo and in vitro models10.3746/pnf.2012.17.1.001 ↗
83. Inhibitory activity of brown algal phlorotannins against glycosidase from the viscera of the turban shell Turbo cornutus10.1017/S0967026202003918 ↗
84. Protective effect of diphlorethohydroxycarmalol isolated from Ishige okamurae against high glucose-induced-oxidative stress in human umbilical vein endothelial cells10.1016/j.fct.2010.02.025 ↗
85. Diphlorethohydroxycarmalol isolated from Pae (Ishige okamurae) protects high glucose0induced damage in RINm5F pancreatic β cells via its antioxidant effects10.1007/s10068-012-0031-3 ↗
86. Ding, Y., Wang, L., Im, S., Hwang, O., Kim, H.-S., Kang, M.-C., and Lee, S.-H. (2019). Anti-obesity effect of diphlorethohydroxycarmalol isolated from brown alga Ishige okamurae in high-fat diet-induced obese mice. Mar. Drugs, 17.10.3390/md17110637 ↗
87. Antidiabetogenic and antioxidant effect of octaphlorethol A isolated from the brown algae Ishige foliacea in streptozotocin-induced diabetic mice10.1007/s10068-014-0173-6 ↗
88. Octaphlorethol A, a novel phenolic compound isolated from Ishige foliacea, protects against streptozotocin-induced pancreatic β cell damage by reducing oxidative stress and apoptosis10.1016/j.fct.2013.07.011 ↗
89. Bioactive compounds inseaweed: Functional food applications and legislation10.1007/s10811-010-9632-5 ↗
90. Mo’o, F.R.C., Wilar, G., Devkota, H.P., and Wathoni, N. (2020). Ulvan, a polysaccharide from Macroalga Ulva sp.: A review of chemistry, biological activities and potential for food and biomedical applications. Appl. Sci., 10.10.3390/app10165488 ↗
91. Shen, P., Yin, Z., Qu, G., and Wang, C. (2018). Fucoidan and its health benefits. Bioact. Seaweeds Food Appl. Nat. Ingred. Healthy Diets, 223–238.10.1016/B978-0-12-813312-5.00011-X ↗
92. Biological activities and potential health benefits of sulfated polysaccharides derived from marine algae10.1016/j.carbpol.2010.10.062 ↗
93. Chapter Seven-Biological Activities of Carrageenan10.1016/B978-0-12-800269-8.00007-5 ↗
94. Pharmacological potential of sulfated polygalactopyranosyl-fucopyranan from the brown seaweed Sragassum wightii10.1007/s10811-017-1385-y ↗
95. Fucoidan-An α-amylase inhibitor from Sargassum wightii with relevance to NIDDM10.1016/j.ijbiomac.2015.08.065 ↗
96. Fucoidan-A α-D-glucosidase inhibitor from Sargassum wightii with relevance to type 2 diabetes mellitus therapy10.1016/j.ijbiomac.2014.10.013 ↗
97. Molecular weight and sulfate content modulate the inhibition of α-amylase by fucoidan relevant for type 2 diabetes management10.1016/j.phanu.2015.02.001 ↗
98. Alpha-amylase and alpha-glucosidase inhibition is differentially modulated by fucoidan obtained from Fucus vesiculosus and Ascophyllum nodosum10.1016/j.phytochem.2013.12.003 ↗
99. Fucoidan from Eclonia maxima is a powerful inhibitor of the diabetes-related enzyme, α-glucosidase10.1016/j.ijbiomac.2020.02.161 ↗
100. In vitro and in vivo hypoglycemic effects of brown algal fucoidans10.1016/j.ijbiomac.2015.11.036 ↗